Cargando…
Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China
COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas. Data were collected from 178 COVID-19 patients overseas...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638095/ https://www.ncbi.nlm.nih.gov/pubmed/36353282 http://dx.doi.org/10.3389/fpubh.2022.1038017 |
_version_ | 1784825332048592896 |
---|---|
author | Huang, Yu-Xuan Li, Na-Fen Li, Chen-Yao Zheng, Fang-Ping Yao, Xiang-Yang Lin, Bao-Hua Huang, Xian-Zhong Zhao, Neng-Jiang Yang, Jia-Yong Chen, Qiu-Min Zhang, Man-Man Yi, Li-Tao Chen, Xue-Qin |
author_facet | Huang, Yu-Xuan Li, Na-Fen Li, Chen-Yao Zheng, Fang-Ping Yao, Xiang-Yang Lin, Bao-Hua Huang, Xian-Zhong Zhao, Neng-Jiang Yang, Jia-Yong Chen, Qiu-Min Zhang, Man-Man Yi, Li-Tao Chen, Xue-Qin |
author_sort | Huang, Yu-Xuan |
collection | PubMed |
description | COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas. Data were collected from 178 COVID-19 patients overseas at First Affiliated Hospital of Xiamen University from April 1, 2021 to July 31, 2021. These patients received therapy of integrated Chinese medicine and western medicine. Demographic data and clinical characteristics were extracted and analyzed. In addition, the prescription which induced less length of PCR positive days and hospitalization days than the median value was obtained. The top 4 frequently used Chinese medicine and virus-related genes were analyzed by network pharmacology and bioinformatics analysis. According to the chest computed tomography (CT) measurement, abnormal lung findings were observed in 145 subjects. The median length of positive PCR/hospitalization days was 7/7 days for asymptomatic subjects, 14/24 days for mild subjects, 10/15 days for moderate subjects, and 14/20 days for severe subjects. The most frequently used Chinese medicine were Scutellaria baicalensis (Huangqin), Glycyrrhiza uralensis (Gancao), Bupleurum chinense (Chaihu), and Pinellia ternata (Banxia). The putative active ingredients were baicalin, stigmasterol, sigmoidin-B, cubebin, and troxerutin. ACE, SARS-CoV-2 3CL, SARS-CoV-2 Spike, SARS-CoV-2 ORF7a, and caspase-6 showed good binding properties to active ingredients. In conclusion, the clinical results showed that integrated Chinese medicine and Western medicine are effective in treating COVID-19 patients from overseas. Based on the clinical outcomes, the putative ingredients from Chinese medicine and the potential targets of SARS-CoV-2 were provided, which could provide a reference for the clinical application of Chinese medicine in treating COVID-19 worldwide. |
format | Online Article Text |
id | pubmed-9638095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96380952022-11-08 Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China Huang, Yu-Xuan Li, Na-Fen Li, Chen-Yao Zheng, Fang-Ping Yao, Xiang-Yang Lin, Bao-Hua Huang, Xian-Zhong Zhao, Neng-Jiang Yang, Jia-Yong Chen, Qiu-Min Zhang, Man-Man Yi, Li-Tao Chen, Xue-Qin Front Public Health Public Health COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas. Data were collected from 178 COVID-19 patients overseas at First Affiliated Hospital of Xiamen University from April 1, 2021 to July 31, 2021. These patients received therapy of integrated Chinese medicine and western medicine. Demographic data and clinical characteristics were extracted and analyzed. In addition, the prescription which induced less length of PCR positive days and hospitalization days than the median value was obtained. The top 4 frequently used Chinese medicine and virus-related genes were analyzed by network pharmacology and bioinformatics analysis. According to the chest computed tomography (CT) measurement, abnormal lung findings were observed in 145 subjects. The median length of positive PCR/hospitalization days was 7/7 days for asymptomatic subjects, 14/24 days for mild subjects, 10/15 days for moderate subjects, and 14/20 days for severe subjects. The most frequently used Chinese medicine were Scutellaria baicalensis (Huangqin), Glycyrrhiza uralensis (Gancao), Bupleurum chinense (Chaihu), and Pinellia ternata (Banxia). The putative active ingredients were baicalin, stigmasterol, sigmoidin-B, cubebin, and troxerutin. ACE, SARS-CoV-2 3CL, SARS-CoV-2 Spike, SARS-CoV-2 ORF7a, and caspase-6 showed good binding properties to active ingredients. In conclusion, the clinical results showed that integrated Chinese medicine and Western medicine are effective in treating COVID-19 patients from overseas. Based on the clinical outcomes, the putative ingredients from Chinese medicine and the potential targets of SARS-CoV-2 were provided, which could provide a reference for the clinical application of Chinese medicine in treating COVID-19 worldwide. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638095/ /pubmed/36353282 http://dx.doi.org/10.3389/fpubh.2022.1038017 Text en Copyright © 2022 Huang, Li, Li, Zheng, Yao, Lin, Huang, Zhao, Yang, Chen, Zhang, Yi and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Huang, Yu-Xuan Li, Na-Fen Li, Chen-Yao Zheng, Fang-Ping Yao, Xiang-Yang Lin, Bao-Hua Huang, Xian-Zhong Zhao, Neng-Jiang Yang, Jia-Yong Chen, Qiu-Min Zhang, Man-Man Yi, Li-Tao Chen, Xue-Qin Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China |
title | Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China |
title_full | Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China |
title_fullStr | Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China |
title_full_unstemmed | Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China |
title_short | Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China |
title_sort | clinical features and effectiveness of chinese medicine in patients with covid-19 from overseas: a retrospective study in xiamen, china |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638095/ https://www.ncbi.nlm.nih.gov/pubmed/36353282 http://dx.doi.org/10.3389/fpubh.2022.1038017 |
work_keys_str_mv | AT huangyuxuan clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT linafen clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT lichenyao clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT zhengfangping clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT yaoxiangyang clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT linbaohua clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT huangxianzhong clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT zhaonengjiang clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT yangjiayong clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT chenqiumin clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT zhangmanman clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT yilitao clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina AT chenxueqin clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina |